--- schema_version: "secwatch.filing_event.v1" accession: "0001628280-26-040812" form_type: "8-K" ticker: "BMRN" cik: "0001048477" company_name: "BIOMARIN PHARMACEUTICAL INC" filed_at: "2026-06-04T20:24:22+00:00" generated_at: "2026-06-04T20:57:34.719343+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.45 calibrated_materiality_score: 0.45 confidence: "high" source: SEC EDGAR --- # BioMarin shareholders approve 7.65M share increase in equity plan; all directors elected ## Summary - Shareholders approved adding 7,650,000 shares to the 2017 Equity Incentive Plan. - All ten director nominees were elected, including CEO Alexander Hardy. - KPMG LLP ratified as BioMarin's independent auditor for FY 2026. - Advisory say-on-pay proposal passed with 142.7M votes for and 21.3M against. ## SEC filing metadata - accession: 0001628280-26-040812 - form_type: 8-K - ticker: BMRN - cik: 0001048477 - company_name: BIOMARIN PHARMACEUTICAL INC - filed_at: 2026-06-04T20:24:22+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.45 - calibrated_materiality_score: 0.45 - confidence: high - sec_items: 5.02, 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000162828026040812/0001628280-26-040812-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000162828026040812/bmrn-20260602.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001628280-26-040812 - JSON: https://secwatch.observer/filing/0001628280-26-040812.json - Plain text: https://secwatch.observer/filing/0001628280-26-040812.txt ## Key facts - Shareholder Votes BIOMARIN PHARMACEUTICAL INC shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-04-07 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2026-04-07 source text: Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin’s independent registered public accounting firm for the fiscal year ending December 31, 2026, as set forth in the Proxy Statement, received the following votes: For Against Abstain 170,867,335 4,850,526 95,431 Based on the votes set forth above, BioMarin’s stockholders ratified the selection of KPMG LLP as BioMarin’s independent registered public accounting firm to serve for the year ending December 31, 2026. evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000162828026040812/0001628280-26-040812-index.htm - Shareholder Votes BIOMARIN PHARMACEUTICAL INC shareholders approved Election of Directors at the 2026-04-07 meeting. - Proposal: director election - Outcome: passed - Meeting: 2026-04-07 source text: Item 5.07 Submission of Matters to a Vote of Security Holders. A total of 193,270,028 shares of common stock were entitled to vote as of April 7, 2026, the record date for the Annual Meeting. There were 175,813,292 shares of common stock present in person or represented by proxy at the Annual Meeting at which the stockholders were asked to vote on four proposals, each of which is described in more detail in the Proxy Statement. Set forth below are the matters acted upon by the stockholders, and the final voting results of each such proposal. Proposal 1: Election of Directors Directors Elected For Against Abstain Broker Non-Votes Elizabeth M. Anderson 152,826,855 11,325,400 41,995 11,619,042 Barbara W. Bodem 162,832,241 796,989 565,020 11,619,042 Ian T. Clark 144,380,101 19,160,530 653,619 11,619,042 Athena Countouriotis 162,326,065 1,823,399 44,786 11,619,042 Willard Dere 161,112,606 2,973,541 108,103 11,619,042 Mark J. Enyedy 161,113,325 3,032,040 48,885 11,619,042 Alexander Hardy 163 evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000162828026040812/0001628280-26-040812-index.htm - Shareholder Votes BIOMARIN PHARMACEUTICAL INC shareholders approved Advisory Vote on the Compensation of Named Executive Officers at the 2026-04-07 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-04-07 source text: Proposal 3: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement, received the following votes: For Against Abstain Broker Non-Votes 142,742,800 21,287,767 163,683 11,619,042 Based on the votes set forth above, BioMarin’s stockholders approved, on an advisory basis, the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement. evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000162828026040812/0001628280-26-040812-index.htm - Shareholder Votes BIOMARIN PHARMACEUTICAL INC shareholders approved Approval of an Amendment to the 2017 Equity Incentive Plan at the 2026-04-07 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2026-04-07 source text: Proposal 4: Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes: For Against Abstain Broker Non-Votes 158,561,867 5,480,380 152,003 11,619,042 Based on the votes set forth above, BioMarin’s stockholders approved the Plan Amendment. evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000162828026040812/0001628280-26-040812-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.